Keppra is the brand name for levetiracetam, an anticonvulsant prescribed for seizure disorders. People taking it sometimes ask whether it will show up on a workplace or clinical drug test, or whether it could be mistaken for an illegal substance. The short answer is that levetiracetam is not a controlled substance, it is not one of the analytes that standard immunoassay drug panels are built to detect, and the published literature does not describe a documented cross reactivity pattern between levetiracetam and the immunoassays used for amphetamines, opiates, cocaine metabolites, PCP, cannabinoids, or benzodiazepines. This article explains how screening and confirmation testing actually work, why levetiracetam sits outside the drugs of abuse categories, and what an employee or employer should do if a prescription medication ever needs to be documented for a drug test result.
What Keppra Is and Why It Differs From a Panel Drug
Levetiracetam is sold under the brand names Keppra and Keppra XR, along with generic versions, and it is approved as adjunctive or monotherapy treatment for certain seizure types. Its labeling, available through the National Library of Medicine's DailyMed label for Keppra XR (levetiracetam), describes it as an antiepileptic drug with a mechanism of action distinct from the opioids, stimulants, and controlled sedatives that drug of abuse panels are designed around. Levetiracetam does not appear on the federal controlled substances schedules, which matters because every analyte a standard urine, oral fluid, or hair panel screens for belongs to one of a small number of pharmacologic classes tied to abuse potential. An anticonvulsant with a different chemical structure and a different mechanism is not automatically assumed to interfere with those assays, and absence of evidence in the toxicology literature is itself informative here. Where a specific claim cannot be confirmed in a published source, the accurate statement is that evidence is limited or absent, not that a result is promised either way.
Screening Immunoassay Versus Confirmation Testing
Workplace and clinical drug testing almost always happens in two stages. The first stage is a screening immunoassay, a fast chemical test where antibodies bind to a target drug class above a set cutoff concentration. Immunoassays are efficient but they work on structural similarity, which is exactly why occasional false positive results happen with other medications that happen to share a molecular shape with a monitored drug class. A widely cited clinical review in the National Library of Medicine's PubMed database, Urine Drug Screening: Practical Guide for Clinicians, walks through the five federal workplace panel classes and the specific medications known to cause interference with each one. Levetiracetam is not among the interferents that review identifies, which is consistent with there being no established cross reactivity pathway for it on standard panels.
The second stage, used whenever a screening result comes back non negative, is confirmation testing by gas chromatography mass spectrometry or liquid chromatography mass spectrometry. Confirmation identifies the exact molecule present rather than a class of similarly shaped molecules, so it is the step that resolves any screening ambiguity. If a screening result were ever non negative for a reason unrelated to levetiracetam, confirmation testing would identify the actual substance responsible rather than reporting levetiracetam itself, because levetiracetam is not the analyte any panel is calibrated to find.
Which Panel Classes Levetiracetam Is Not Part Of
Standard five panel, seven panel, ten panel, and twelve panel workplace tests, the kind collected with a point of collection multi panel drug test cup, screen for amphetamines and methamphetamine, cannabinoids (THC), cocaine metabolites, opiates, PCP, and depending on the panel, benzodiazepines, barbiturates, methadone, and a handful of other classes. Levetiracetam is chemically unrelated to every one of those categories. It is not an amphetamine analog, not an opioid, not a cannabinoid, not a benzodiazepine, and not a barbiturate. That is distinct from some other seizure medications, a point covered in more detail in the table below and in a related post on whether topiramate shows up on a drug test, since not every anticonvulsant sits in the same regulatory category.
Therapeutic Drug Monitoring Is a Different Test Entirely
There is a scenario where a laboratory does measure levetiracetam directly, but it is not a drug of abuse screen. A prescriber may order therapeutic drug monitoring, typically a blood or serum test, to check whether levetiracetam is present at a level consistent with the prescribed dose, to assess adherence, or to adjust a seizure treatment plan. That test is ordered by a treating clinician for medical management, uses a different specimen and a different assay target than a workplace urine panel, and is not something a general employment drug screen performs. Mixing up therapeutic drug monitoring with workplace drug of abuse screening is a common source of confusion, and the two should not be described as the same kind of test.
Common Seizure Medications and Panel Notes
| Medication | Drug class | Federally controlled | Panel note |
|---|---|---|---|
| Levetiracetam (Keppra) | Anticonvulsant | No | Not a target analyte; no established cross reactivity in published reviews |
| Topiramate (Topamax) | Anticonvulsant | No | Not a target analyte; see the dedicated topiramate post for panel specific notes |
| Lamotrigine (Lamictal) | Anticonvulsant | No | Not a target analyte on standard panels |
| Carbamazepine (Tegretol) | Anticonvulsant | No | Not a drug of abuse target; any non negative screen still requires confirmation and MRO review |
| Phenytoin (Dilantin) | Anticonvulsant | No | Not a target analyte on standard panels |
| Clonazepam (Klonopin) | Benzodiazepine | Yes, Schedule IV | Expected to register on a benzodiazepine panel; prescription documentation is the correct response |
| Phenobarbital | Barbiturate | Yes, Schedule IV | Expected to register on a barbiturate panel; prescription documentation is the correct response |
The pattern in that table is the point. Several anticonvulsants, levetiracetam included, sit outside every panel class entirely. A smaller number of seizure medications, such as clonazepam and phenobarbital, are themselves federally controlled and are expected to appear on the panel built for their own class, which is a normal and explainable result, not an error.
What the Medical Review Officer Process Covers
Every non negative screening result in a regulated or employer sponsored program is reviewed by a medical review officer, a licensed physician trained to interpret laboratory results and confirmed findings in the context of legitimate medical explanations. The Substance Abuse and Mental Health Services Administration maintains program guidance for this role on its workplace resources page, and the duties, confidentiality requirements, and verification steps for medical review officers in federally regulated testing programs are set out in 49 CFR Part 40, Subpart G. A more complete walkthrough of that process is available in a related post, the medical review officer process explained for employers. In practice, if a laboratory confirms a non negative result, the medical review officer contacts the employee privately, asks about current prescriptions and medical conditions, and may verify a prescription with the pharmacy or prescribing clinician before a final result is reported. An employee taking levetiracetam or any other seizure medication should keep current prescription documentation available and disclose it if asked, rather than assume no question will come up.
What an Employee or Employer Should Actually Do
An employee prescribed Keppra does not need to stop, adjust, or hide the medication before a scheduled drug test. The correct step is disclosure through the normal channel the collection site or employer provides, along with keeping a pharmacy label or prescription record on hand in case the medical review officer needs to verify it. Employers should never instruct a worker to alter a prescribed medication schedule around a test date, and decisions about fitness for duty related to a seizure disorder generally involve the prescribing clinician and, where relevant, human resources or legal counsel rather than the testing process itself. None of this is medical advice, and any question about dosing, seizure control, or whether a medication is safe to continue belongs with the prescribing physician, not with a testing policy.
Why the Confirmation Step Protects Everyone
Because confirmation testing by gas chromatography mass spectrometry or liquid chromatography mass spectrometry identifies the specific molecule in a specimen, it is the safeguard against any false attribution at the screening stage, for levetiracetam or any other medication. A result is never finalized on an immunoassay screen alone in a quality program. That two step design, screen first, confirm second, verify through a medical review officer third, is why employers can rely on a documented process rather than a single test strip, and why employees taking legitimate prescriptions have a clear path to resolve a result rather than guess at one.
Frequently Asked Questions
Does Keppra show up as a positive result for an illegal drug on a standard panel?
No. Levetiracetam is not a target analyte on standard amphetamine, opiate, cocaine, PCP, cannabinoid, or benzodiazepine immunoassays, and published toxicology reviews do not document a cross reactivity pattern for it.
Is levetiracetam a controlled substance?
No. Levetiracetam does not appear on the federal controlled substances schedules, which is part of why it is not included as a panel target on workplace or clinical drug of abuse screens.
Will a drug test specifically detect levetiracetam in my system?
Only if a clinician orders therapeutic drug monitoring, a separate blood or serum test used to check medication levels for medical management. Standard workplace urine panels are not built to detect levetiracetam.
What should someone taking Keppra do before a workplace drug test?
Disclose the medication through the normal collection or employer process and keep prescription documentation available in case the medical review officer needs to verify it. There is no need to alter the medication schedule.
Can other seizure medications cause a positive drug screen?
Some can. A small number of anticonvulsants used for seizures, such as clonazepam and phenobarbital, are themselves federally controlled substances and are expected to register on the panel built for their class. That outcome is resolved through confirmation testing and medical review officer verification of the prescription.
What is the difference between a screening test and a confirmation test?
A screening immunoassay is a fast test that flags a specimen as non negative above a set cutoff for a drug class. A confirmation test, using gas chromatography mass spectrometry or liquid chromatography mass spectrometry, identifies the specific molecule present and is required before any non negative screening result is reported as final.
This article is general information about drug testing science and process, not legal or medical advice. Anyone with questions about a medication, a seizure condition, or a specific test result should talk to a licensed physician or the medical review officer handling the case.
